Best practice

Rapid reporting of substandard and falsified medicines

One in every 10 medicinal products in low- and middle-income countries is substandard or falsified.

Explore further

How we measure

How we measure

The Index evaluates pharmaceutical companies in areas where they have the biggest potential and responsibility to make change, such as R&D and pricing. Find out more about the analytical framework and areas of evaluation.

Get in touch

Back to top |